70. A PHASE 1–2 CLINICAL TRIAL OF EO1001, A NOVEL IRREVERSIBLE pan-ErbB INHIBITOR WITH PROMISING BRAIN PENETRATION

CNS metastasis has become a prominent driver of morbidity and mortality in recent years as new targeted therapies have improved systemic outcomes. Mutations in the ErbB family of kinases are known oncodrivers in many of these cancers. ErbB family member “crosstalk” is associated with rapid developme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Wheeler, Helen, Bacha, Jeffrey, Kanekal, Sarath, Pedersen, Harry, Sankar, Neil, Wang, Shen, Nesbit, Ian, Skoff, Kathy, Brown, Dennis
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Supplement Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7401413/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa073.057
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados